3 Results for "

PD-L1/HDAC-IN-1

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "PD-L1/HDAC-IN-1" in MCE Product Catalog:

Cat. No.: HY-172167
CAS No.: 2923313-69-1
Target:  

PD-1/PD-L1 HDAC

Research Areas:  

Inflammation/Immunology Cancer

PD-L1/HDAC-IN-1 (Compound 14) is the inhibitor for PD-L1 and HDAC that inhibits PD-1/PD-L1 interaction, HDAC2 and HDAC3 with IC50 of 88.10, 27.98 and 14.47 nM, respectively. PD-L1/HDAC-IN-1 exhibits slight cytotoxicity in MCF-7 (IC50=19.34 μM). PD-L1/HDAC-IN-1 upregulates the expression of PD-L1 and CXCL10, promoting anti-tumour immune response by recruiting T-cell infiltration into TME [1].
loading...
    loading...
Cat. No.: HY-159172
CAS No.: 2988762-46-3
Target:  

HDAC

Research Areas:  

Cancer

HDAC3-IN-4 is a selective and orally active HDAC3 inhibitor with an IC50 of 89 nM. HDAC3-IN-4 induces the degradation of PD-L1 by regulating cathepsin B (CTSB) in the lysosomes, with a DC50 of 5.7 μM. HDAC3-IN-4 shows better selectivity for HDAC3 over HDAC1, HDAC6, HDAC7, and HDAC8 .
loading...
    loading...
Cat. No.: HY-187370
Target:  

HDAC PAK PD-1/PD-L1

Research Areas:  

Cancer

YDH-704 is a PAK1/HDAC10 inhibitor, with IC50 values of 0.05 μM and 0.02 μM against human targets, respectively. YDH-704 blocks PAK1-mediated oncogenic signaling pathways, inhibits the proliferation and migration of tumor cells, suppresses the epigenetic regulatory function of HDAC10, downregulates PD-L1 expression, and regulates polyamine metabolism. YDH-704 reduces MDSC/Treg infiltration, enhances the infiltration and activation of CD8 + T cells, and inhibits tumor growth and lung metastasis. YDH-704 can be used for research on triple-negative breast cancer [1].
loading...
    loading...